AR039927A1 - Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen - Google Patents
Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR039927A1 AR039927A1 ARP030101923A AR039927A1 AR 039927 A1 AR039927 A1 AR 039927A1 AR P030101923 A ARP030101923 A AR P030101923A AR 039927 A1 AR039927 A1 AR 039927A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- hydrogen
- linear
- atoms
- heteroaryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical class C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 17
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 206010061216 Infarction Diseases 0.000 abstract 2
- 229910003827 NRaRb Inorganic materials 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 230000007574 infarction Effects 0.000 abstract 2
- 208000028867 ischemia Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- -1 S (O) nR7 Chemical group 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000003293 cardioprotective effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000035778 pathophysiological process Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Los compuestos son adecuados como medicamentos antiarrítmicos con un componente cardioprotector para la profilaxis del infarto y el tratamiento del infarto y para el tratamiento de la angina de pecho. Dichos derivados inhiben también de manera preventiva los procesos patofisiológicos asociados con el desarrollo del dano inducido por isquemia, en particular en el desencadenamiento de arritmias cardíacas inducidas por isquemia y de la insuficiencia cardiaca. Reivindicación 1: Compuesto de la fórmula (1): en la cual R1 y R2 son, independientemente uno del otro, hidrógeno, alquilo que tiene 1, 2, 3 ó 4 átomos de carbono, alquenilo que tiene 2, 3, 4, 5 ó 6 átomos de carbono, alquinilo que tiene 2, 3, 4, 5 ó 6 átomos de carbono, arilo, heteroarilo, F, Cl, Br, I, NO2, NH2, alquilamino que tiene 1, 2, 3 ó 4 átomos de carbono, NRaRb, alquilcarbonilamino que tiene 1, 2, 3 ó 4 átomos de carbono, OH, alcoxi que tiene 1, 2, 3 ó 4 átomos de carbono, S(O)nR7, CO2H, alcoxicarbonilo que tiene 1, 2, 3 ó 4 átomos de carbono, alquilcarbonilo que tiene 1, 2, 3 ó 4 átomos de carbono, CONH2, CONRaRb, CN, polifluoroalquilo que tiene 1, 2, 3 ó 4 átomos de carbono, polifluoroalcoxi que tiene 1, 2 ó 3 átomos de carbono o SO3H; estando sustituidos opcionalmente a su vez R1 y R2 por un grupo alquilo lineal o ramificado que tiene 1, 2, 3 ó 4 átomos de carbono; n es cero, 1 ó 2; R3 es hidrógeno, arilo, heteroarilo, un grupo del tipo Alk-R8 o cicloalquilo que tiene 3, 4, 5, 6, 7 ó 8 átomos de carbono; en el cual cicloalquilo está sustituido opcionalmente con uno o más sustituyentes seleccionados del grupo F, CI, Br o I, Alk es alquilo que tiene 1, 2, 3, 4 ó 5 átomos de carbono en una cadena lineal o ramificada, R8 es hidrógeno, cicloalquilo que tiene 3, 4, 5, 6, 7 o 8 átomos de carbono, polifluoroalquilo que tiene 1, 2, 3, ó 4 átomos de carbono, arilo, heteroarilo, OH, alcoxi que tiene 1, 2, 3 ó 4 átomos de carbono, CO2H, CONH2, CONRaRb, NH2, alquilamino que tiene 1, 2, 3 ó 4 átomos de carbono o NRaRb; R4, R5 y R6 son, independientemente unos de otros, hidrógeno o un alquilo lineal o ramificado que tiene 1, 2, 3 ó 4 átomos de carbono; R7 es un alquilo lineal o ramificado que tiene 1, 2, 3 ó 4 átomos de carbono; Ra y Rb se definen, independientemente uno de otro, como R7, o, alternativamente Ra y Rb forman, junto con el átomo de nitrógeno al cual están unidos, un heterociclo de 5 ó 6 miembros que contiene opcionalmente otro heteroátomo seleccionado de O, S o N; y mezclas racémicas, enantiómeros y diastereoisómeros de los mismos y mezclas de ellos, sus tautómeros y sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0206783A FR2840302B1 (fr) | 2002-06-03 | 2002-06-03 | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039927A1 true AR039927A1 (es) | 2005-03-09 |
Family
ID=29558914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101923 AR039927A1 (es) | 2002-06-03 | 2003-05-30 | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US7078428B2 (es) |
| EP (1) | EP1528923B1 (es) |
| JP (1) | JP4634793B2 (es) |
| KR (1) | KR101149771B1 (es) |
| CN (1) | CN1290833C (es) |
| AR (1) | AR039927A1 (es) |
| AT (1) | ATE324889T1 (es) |
| AU (1) | AU2003240677B2 (es) |
| BR (1) | BR0311556A (es) |
| CA (1) | CA2488373C (es) |
| CY (1) | CY1105115T1 (es) |
| DE (1) | DE60305042T2 (es) |
| DK (1) | DK1528923T3 (es) |
| EC (1) | ECSP045472A (es) |
| EG (1) | EG24784A (es) |
| ES (1) | ES2261939T3 (es) |
| FR (1) | FR2840302B1 (es) |
| HN (1) | HN2003000162A (es) |
| HR (1) | HRP20041151B1 (es) |
| IL (1) | IL165520A (es) |
| JO (1) | JO2357B1 (es) |
| MA (1) | MA27308A1 (es) |
| ME (1) | MEP27508A (es) |
| MX (1) | MXPA04011931A (es) |
| MY (1) | MY142502A (es) |
| NO (1) | NO329224B1 (es) |
| NZ (1) | NZ536953A (es) |
| OA (1) | OA12864A (es) |
| PA (1) | PA8574701A1 (es) |
| PE (1) | PE20040531A1 (es) |
| PL (1) | PL372188A1 (es) |
| PT (1) | PT1528923E (es) |
| RS (1) | RS51636B (es) |
| RU (1) | RU2318809C2 (es) |
| SI (1) | SI1528923T1 (es) |
| TN (1) | TNSN04237A1 (es) |
| TW (1) | TWI286545B (es) |
| UA (1) | UA81118C2 (es) |
| UY (1) | UY27835A1 (es) |
| WO (1) | WO2003101450A1 (es) |
| ZA (1) | ZA200409094B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7531569B2 (en) | 2003-12-02 | 2009-05-12 | Sanofi-Aventis Deutschland Gmbh | Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives |
| DE10356717A1 (de) * | 2003-12-02 | 2005-07-07 | Aventis Pharma Deutschland Gmbh | Verfahren zur Herstellung von (3-Oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-Derivaten |
| KR100518184B1 (ko) * | 2003-12-27 | 2005-10-04 | 한국화학연구원 | 퓨란카보닐구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물 |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| WO2007047646A2 (en) * | 2005-10-14 | 2007-04-26 | Janssen Pharmaceutica, N.V. | Substituted dihydro-isoindolones useful in treating kinase disorders |
| TW200812962A (en) * | 2006-07-12 | 2008-03-16 | Astrazeneca Ab | New compounds I/418 |
| TWI417100B (zh) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途 |
| SA109300358B1 (ar) | 2008-06-06 | 2012-11-03 | استرازينيكا ايه بي | مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون |
| GB0811643D0 (en) * | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| WO2012003147A1 (en) * | 2010-07-01 | 2012-01-05 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
| TW201321371A (zh) | 2011-10-14 | 2013-06-01 | Incyte Corp | 做為ａｋｔ抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物 |
| CN103193794B (zh) * | 2013-04-12 | 2016-04-06 | 中国药科大学 | 一种异吲哚酮并异噁唑类稠环化合物及其合成方法 |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| CN106316922B (zh) * | 2016-08-17 | 2019-02-01 | 华东师范大学 | 一种含c-3全取代氧化吲哚衍生物及其合成方法和应用 |
| WO2018058109A1 (en) | 2016-09-26 | 2018-03-29 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CN110664803B (zh) * | 2019-09-19 | 2023-08-29 | 中山大学 | 异吲哚酮类化合物在制备防治溶骨性疾病药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2708605A1 (fr) * | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| ES2107698T3 (es) | 1993-02-20 | 1997-12-01 | Hoechst Ag | Benzoilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento, como inhibidores del intercambio celular de na+/h+ o como agente de diagnostico, asi como medicamento que las contiene. |
| FR2735166B1 (fr) * | 1995-06-08 | 1997-08-29 | Aerospatiale | Procede de fabrication d'un panneau ou analogue a proprietes structurale et acoustique et panneau ainsi obtenu |
| DE19737224A1 (de) | 1997-08-27 | 1999-03-18 | Hoechst Marion Roussel De Gmbh | Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen |
| DE19737463A1 (de) | 1997-08-28 | 1999-03-04 | Hoechst Marion Roussel De Gmbh | Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden |
| DE19738604A1 (de) | 1997-09-04 | 1999-03-11 | Hoechst Marion Roussel De Gmbh | Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verminderung der Giftigkeit cardiotoxischer Stoffe |
| KR100407903B1 (ko) | 1998-02-27 | 2003-12-01 | 화이자 프로덕츠 인크. | 허혈 치료용 ｎ-[(치환된 5원 트리아자 이불포화고리)카르보닐] 구아니딘 유도체 |
| DE19859727A1 (de) | 1998-12-23 | 2000-06-29 | Aventis Pharma Gmbh | Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung |
| US6534651B2 (en) * | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| OA12256A (en) * | 2000-04-28 | 2003-11-06 | Pfizer Prod Inc | Sodium-hydrogen exchanger type 1 inhibitor (NHE-1). |
| DE10046993A1 (de) * | 2000-09-22 | 2002-04-11 | Aventis Pharma Gmbh | Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament |
| DE60216747T2 (de) * | 2001-04-09 | 2007-10-04 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten |
-
2002
- 2002-06-03 FR FR0206783A patent/FR2840302B1/fr not_active Expired - Fee Related
-
2003
- 2003-05-07 JO JO200351A patent/JO2357B1/en active
- 2003-05-20 ME MEP27508 patent/MEP27508A/xx unknown
- 2003-05-20 WO PCT/EP2003/005279 patent/WO2003101450A1/en not_active Ceased
- 2003-05-20 RS YUP104804 patent/RS51636B/sr unknown
- 2003-05-20 CN CNB038128500A patent/CN1290833C/zh not_active Expired - Fee Related
- 2003-05-20 CA CA 2488373 patent/CA2488373C/en not_active Expired - Fee Related
- 2003-05-20 KR KR1020047019619A patent/KR101149771B1/ko not_active Expired - Fee Related
- 2003-05-20 UA UA20041211001A patent/UA81118C2/uk unknown
- 2003-05-20 PL PL37218803A patent/PL372188A1/xx unknown
- 2003-05-20 OA OA1200400323A patent/OA12864A/en unknown
- 2003-05-20 MX MXPA04011931A patent/MXPA04011931A/es active IP Right Grant
- 2003-05-20 DK DK03730076T patent/DK1528923T3/da active
- 2003-05-20 NZ NZ536953A patent/NZ536953A/en not_active IP Right Cessation
- 2003-05-20 JP JP2004508808A patent/JP4634793B2/ja not_active Expired - Fee Related
- 2003-05-20 DE DE2003605042 patent/DE60305042T2/de not_active Expired - Lifetime
- 2003-05-20 PT PT03730076T patent/PT1528923E/pt unknown
- 2003-05-20 BR BR0311556A patent/BR0311556A/pt not_active IP Right Cessation
- 2003-05-20 HR HRP20041151AA patent/HRP20041151B1/hr not_active IP Right Cessation
- 2003-05-20 EP EP20030730076 patent/EP1528923B1/en not_active Expired - Lifetime
- 2003-05-20 AT AT03730076T patent/ATE324889T1/de active
- 2003-05-20 AU AU2003240677A patent/AU2003240677B2/en not_active Ceased
- 2003-05-20 RU RU2004138789A patent/RU2318809C2/ru not_active IP Right Cessation
- 2003-05-20 ES ES03730076T patent/ES2261939T3/es not_active Expired - Lifetime
- 2003-05-20 SI SI200330302T patent/SI1528923T1/sl unknown
- 2003-05-27 US US10/445,618 patent/US7078428B2/en not_active Expired - Lifetime
- 2003-05-29 PE PE2003000523A patent/PE20040531A1/es not_active Application Discontinuation
- 2003-05-30 HN HN2003000162A patent/HN2003000162A/es unknown
- 2003-05-30 AR ARP030101923 patent/AR039927A1/es active IP Right Grant
- 2003-05-30 TW TW92114642A patent/TWI286545B/zh not_active IP Right Cessation
- 2003-06-01 EG EG2003060521A patent/EG24784A/xx active
- 2003-06-02 PA PA8574701A patent/PA8574701A1/es unknown
- 2003-06-02 MY MYPI20032036 patent/MY142502A/en unknown
- 2003-06-03 UY UY27835A patent/UY27835A1/es unknown
-
2004
- 2004-11-10 ZA ZA2004/09094A patent/ZA200409094B/en unknown
- 2004-11-16 MA MA27951A patent/MA27308A1/fr unknown
- 2004-11-30 TN TNP2004000237A patent/TNSN04237A1/en unknown
- 2004-12-02 IL IL165520A patent/IL165520A/en not_active IP Right Cessation
- 2004-12-02 EC ECSP045472 patent/ECSP045472A/es unknown
- 2004-12-27 NO NO20045660A patent/NO329224B1/no not_active IP Right Cessation
-
2006
- 2006-03-01 US US11/365,319 patent/US7589117B2/en not_active Expired - Fee Related
- 2006-07-28 CY CY20061101057T patent/CY1105115T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039927A1 (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen | |
| PE20040373A1 (es) | Composiciones herbicidas que comprenden derivados de isoxazolina | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR036663A1 (es) | Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios, las composiciones farmaceuticas que las contienen y los intermediarios para preparar dichos compuestos | |
| CU23413B7 (es) | Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
| AR076900A1 (es) | Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc | |
| AR039933A1 (es) | Indoles sustituidos para tratamiento de desordenes respiratorios | |
| AR055116A1 (es) | Compuestos aromaticos como agentes terapeuticos para diabetes y composiciones farmaceuticas que los contienen. | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| EA201170546A1 (ru) | Новые гетероциклические азотсодержащие соединения, их получение и их применение в качестве антибактериальных лекарственных средств | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| EA201170522A1 (ru) | Новые гетероциклические азотсодержащие соединения, их получение и их применение в качестве антибактериальных лекарственных средств | |
| ECSP099682A (es) | Nuevos compuestos heterociclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos | |
| AR059032A1 (es) | Combinacion de derivados de triazina y sensibilizadores de insulina | |
| AR038147A1 (es) | Compuestos derivados del acido fenil(alquil)carboxilico y compuestos derivados fenilalquilheterociclicos dionicos, su empleo y composiciones farmaceuticas que los contienen | |
| AR074700A1 (es) | Derivados heterociclicos fusionados con oxadiazola, composiciones farmaceuticas, procesos de preparacion y su uso en el tratamiento de esclerosis multiple y otras enfermedades | |
| AR040564A1 (es) | Derivados de 3 guanidinocarbonil- 1- heteroaril- indol, procedimiento de preparacion, su uso como medicamentos, y composiciones farmaceuticas que los comprenden | |
| AR040034A1 (es) | Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o compuesto auxiliar de diagnostico, y un medicamento que las comprende | |
| AR059031A1 (es) | Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasa | |
| AR040563A1 (es) | Derivados de 3- guanidincarbonil - 1 heteroaril pirrol, procedimiento de preparacion e intermediarios de este procedimientosu, uso como medicamentos y composiciones farmaceuticas que los comprenden | |
| AR053453A1 (es) | Derivados de aminoalquil- y amidoalquil-benzopirano substituidos | |
| ES2183434T3 (es) | Derivados de cromano sustituidos con carboxilo utiles como agonistas de adrenoreceptores. | |
| AR040565A1 (es) | Derivados de 3- guanidocarbonil 1-heteroaril - indol, procedimiento de preparacion, su uso como medicamentos y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |